Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS006 versus cyclosporine in primary membranous nephropathy
ChiCTR2400091563Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Oct 2024
- Modality
- Small Molecules, Peptides, IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of hlx01 and cyclosporine in idiopathic membranous glomerulonephritis (IMG) (3 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Proportion of subjects achieving overall remission at week 76. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
hlx01cyclosporine
03
Conditions
idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on ChiCTR2400091563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091563.